Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
General Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign In
or
Register
to read more
14673
Related Questions
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
How do you approach management for CCUS with severe cytopenias?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
How do you decide the dose of aspirin to use in MPN patients?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
How does triple-negative status influence your management of ET?
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?